Work

Supplementary Data from Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Data from Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial

DOI: 10.1158/1078-0432.22486286.v1

Authors: Thomas Denize, Subrina Farah, Alessia Cimadamore, Abdallah Flaifel, Emily Walton, Maura A. Sticco-Ivins, Chris Labaki, David A. Braun, Maxine Sun, Evelyn Wang, Wanling Xie, Toni K. Choueiri, Sabina Signoretti

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361812792

Cites:

Cited by:

Related to: 10